Frazier Life Sciences Management, L.P. Krystal Biotech, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.9 Billion
- Q1 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 988,460 shares of KRYS stock, worth $182 Million. This represents 9.23% of its overall portfolio holdings.
Number of Shares
988,460
Previous 988,460
-0.0%
Holding current value
$182 Million
Previous $123 Million
43.42%
% of portfolio
9.23%
Previous 7.54%
Shares
7 transactions
Others Institutions Holding KRYS
# of Institutions
262Shares Held
21.5MCall Options Held
462KPut Options Held
723K-
Avoro Capital Advisors LLC New York, NY2.56MShares$469 Million5.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.43MShares$447 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.81MShares$332 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA1.51MShares$277 Million10.58% of portfolio
-
State Street Corp Boston, MA945KShares$173 Million0.01% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.71B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...